Launch week offerEnds in00h00m00s
annual Promonthly Pro
Anke Salmen
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (16)
Year:
2025
Background: Reporting of sex-specific analyses in multiple sclerosis (MS) is sparse. Disability accrual results from relapses (relapse-associated worsening) and independent thereof (progression independent of relapses). Objectives: A population of MS patients during relapse treated per standard of care was analyzed for sex differences and short-term relapse outcome (3–6 months) as measured by Expanded Disability Status Scale (EDSS) change. Design: Single-center retrospective study. Methods: We analyzed 134 MS relapses between March 2016 and August 2020. All events required relapse treatment (steroids and/or plasma exchange). Demographic, disease, and paraclinical characteristics [cerebrospinal fluid (CSF) and magnetic resonance imaging (MRI)] were displayed separated by sex. Multivariable linear regression was run to identify factors associated with short-term EDSS change. Results: Mean age at relapse was 38.4 years (95% confidence interval: 36.3–40.4) with a proportion of 71.6% women in our cohort. Smoking was more than twice as prevalent in men (65.8%) than women (32.3%). In- and after-relapse EDSSs were higher in men [men: 3.3 (2.8–3.9), women: 2.7 (2.4–3.0); men: 3.0 (1.3–3.6); women: 1.8 (1.5–2.1)] despite similar relapse intervention. Paraclinical parameters revealed no sex differences. Our primary model identified female sex, younger age, and higher EDSS at relapse to be associated with EDSS improvement. A higher immunoglobulin G (IgG) quotient (CSF/serum) was associated with poorer short-term outcome [mean days between first relapse treatment and last EDSS assessment 130.2 (79.3–181.0)]. Conclusion: Sex and gender differences are important in outcome analyses of MS relapses. Effective treatment regimens need to respect putative markers for a worse outcome to modify long-term prognosis such as clinical and demographic variables, complemented by intrathecal IgG synthesis. Prospective trials should be designed to address these differences and confirm our results.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (12)
Caroline Pot
Associate Professor
Lausanne University Hospital
Özgür Yaldizli
-
Ramona-Alexandra Todea
University Hospital of Zurich
Stefanie Marti
University Hospital of Bern
Mario Ocampo-Pineda
University of Basel
Helly Hammer
University Hospital of Bern
Robert Hoepner
Head of Neuroimmunological Outpatient Department and Neuroimmunological Study Cetner
University Hospital of Bern
Philippe C. Cattin
Department Head
University of Basel
Andrew Chan
Chief Physician, Deputy Head of Department, Head of Medical Division Neuro
University Hospital of Bern
Martina Absinta
Humanitas University
Ludwig Kappos
Professor
University of Basel
Alessandro Cagol
-
Make your next move.
Prepare your application
Review drafts before you send them.